Select Page

South Delhi Pharma, New Delhi, India

SUTENT (sunitinib malate) capsules, oral

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

Facts of Sutent (sunitinib malate)

Product: SUTENT® (sunitinib malate) capsules, oral
Initial U.S. Approval: 2006
Strength: Capsules: 12.5 mg, 25 mg, 50 mg
Company: Pfizer, Inc
Indication: Treatment of Gastrointestinal stromal tumor (GIST), Advanced renal cell carcinoma (RCC), pancreatic neuroendocrine tumors (pNET)

South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Sutent (sunitinib malate)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Sutent (sunitinib malate) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

What Sutent is?

SUTENT is a kinase inhibitor indicated for the treatment of:
• Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.
• Advanced renal cell carcinoma (RCC).
• Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease.

What Sunitinib is?

Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.

Reviews

There are no reviews yet.

Be the first to review “SUTENT (sunitinib malate) capsules, oral”

Your email address will not be published.